What is LB Pharmaceuticals Inc's (LBRX) StockRank?

MoatMap's StockRank for LB Pharmaceuticals Inc (LBRX) is 32/100, with a Sell signal. This is a composite score combining Quality (45), Value (41), and Momentum (38) factor ranks across MoatMap's 20,000+ stock universe.

Does LB Pharmaceuticals Inc have an economic moat?

LB Pharmaceuticals Inc (LBRX) has a Quality factor score of 45/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is LB Pharmaceuticals Inc a buy, hold, or sell?

MoatMap's current signal for LB Pharmaceuticals Inc (LBRX) is Sell, based on a StockRank of 32/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is LB Pharmaceuticals Inc in?

LB Pharmaceuticals Inc (LBRX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

LBRX

SELLREMOVE

LB Pharmaceuticals Inc · Healthcare · United States · $789M · Avg Vol: $5M/d

StockRank

P/E (TTM)

—

ROE

-19.6%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

LB Pharmaceuticals is a micro-cap clinical-stage biotech company with binary drug trial risks. It lacks the established cash flows, high ROIC, and structural moats required for our concentrated quality book.

COMPANY DESCRIPTION

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for central nervous system disorders. The company's lead candidate, LB-102, is being investigated for schizophrenia, targeting a new mechanism of action. LB Pharmaceuticals aims to address the significant need for improved therapies in psychiatric conditions through its innovative drug discovery efforts.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-4.05	-1.77	-17.82	-3.13	—
Shares	22.4M	22.4M	22.4M	25.3M	+12.7%
Debt	24.1M	0	3.7M	3.6M	-47.1%
Equity	-28.8M	-34.5M	-94.6M	301.3M	—
Op CF	-2.7M	-12.1M	-53.1M	-35.2M	—
Inv CF	0.1M	-28.0M	23.2M	-39.9M	—
Fin CF	23.0M	33.7M	38.3M	302.6M	—

PRICE (1Y)-6.2%

SMA 50SMA 200

$30.00

RSI (14)

61.5

SCORE BREAKDOWN

Quality

ROIC

-10.0%34.3

ROE

-19.6%30.1

GP/Assets

—N/A

Op. Margin

0.0%40.4

FCF/Assets

—N/A

Piotroski

321.6

Int. Cover

—N/A

D/E Ratio

0.01x89.0

Current Ratio

35.67x98.7

Value

P/E (TTM)

—N/A

EV/EBITDA

-10.1x81.7

P/FCF

—N/A

P/B

2.2x52.6

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

—N/A

RS 6M

40%91.9

SMA 50/200

—N/A

EPS Rev 4W

-0.3%37.8

EPS Rev 12W

—N/A

EPS Improve

-230%1.9

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$789M

P/E (Forward)

-6.3x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LBRX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
LBRX	LB Pharmaceuticals Inc(you)	$789M	32	SELL
PHAT	Phathom Pharmaceuticals, Inc.	$823M	33	SELL
ALLO	Allogene Therapeutics, Inc.	$777M	28	SELL
ANL	Adlai Nortye Ltd.	$728M	35	HOLD
AURA	Aura Biosciences, Inc.	$775M	27	SELL
ANNX	Annexon, Inc.	$880M	28	SELL
CRVS	Corvus Pharmaceuticals, Inc.	$1.1B	33	SELL
JBIO	Jade Biosciences, Inc.	$1.0B	34	SELL
ACRS	Aclaris Therapeutics, Inc.	$638M	35	HOLD
MNKD	MannKind Corporation	$1.1B	31	SELL

Peer medians: ROE -22.7% · P/E 25.3x · Gross margin 44.3%

LB Pharmaceuticals Inc (LBRX) — Stock Score Summary

LB Pharmaceuticals Inc (LBRX) has a MoatMap StockRank of 32/100 based on Quality (45/100), Value (41/100), and Momentum (38/100) factor scores. The current signal is SELL. LB Pharmaceuticals is a micro-cap clinical-stage biotech company with binary drug trial risks. It lacks the established cash flows, high ROIC, and structural moats required for our concentrated quality book.

Key Financial Metrics

Price	$30.00
Market Cap	$789M
P/E (Forward)	-6.33
Price/Book	2.15
Return on Equity	-19.6%
Return on Invested Capital	-10.0%
Debt/Equity	0.92
Gross Margin	0.0%
Operating Margin	0.0%

LB Pharmaceuticals Inc operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is LB Pharmaceuticals Inc’s (LBRX) StockRank?: MoatMap’s StockRank for LB Pharmaceuticals Inc (LBRX) is 32/100, with a Sell signal. It is a composite of Quality (45), Value (41), and Momentum (38) factor ranks across MoatMap’s 20,000+ stock universe.
Does LB Pharmaceuticals Inc have an economic moat?: LB Pharmaceuticals Inc (LBRX) has a Quality factor score of 45/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is LB Pharmaceuticals Inc a buy, hold, or sell?: MoatMap’s current signal for LB Pharmaceuticals Inc (LBRX) is Sell, based on a StockRank of 32/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is LB Pharmaceuticals Inc in?: LB Pharmaceuticals Inc (LBRX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).